Amgen Inc. $AMGN Stock Sold by Philadelphia Trust Co.

Philadelphia Trust Co. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 9.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,164 shares of the medical research company’s stock after selling 3,632 shares during the period. Amgen accounts for about 0.9% of Philadelphia Trust Co.’s portfolio, making the stock its 28th largest holding. Philadelphia Trust Co.’s holdings in Amgen were worth $13,979,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Rational Advisors Inc. grew its holdings in shares of Amgen by 13.7% during the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after purchasing an additional 24 shares during the period. Beacon Financial Advisory LLC raised its holdings in Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after buying an additional 25 shares during the period. James T. Borello RIA raised its holdings in Amgen by 13.6% in the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock valued at $88,000 after buying an additional 25 shares during the period. Sweeney & Michel LLC raised its holdings in Amgen by 0.5% in the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock valued at $2,162,000 after buying an additional 25 shares during the period. Finally, Legacy Financial Advisors Inc. lifted its position in Amgen by 0.8% in the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after buying an additional 26 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Performance

Shares of Amgen stock opened at $465.23 on Wednesday. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company has a market cap of $251.65 billion, a PE ratio of 26.99, a P/E/G ratio of 3.25 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The business has a 50-day simple moving average of $423.79 and a 200-day simple moving average of $379.39.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.64 earnings per share. On average, equities research analysts forecast that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s payout ratio is 58.47%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AMGN shares. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Leerink Partners upped their price objective on shares of Amgen from $395.00 to $464.00 and gave the stock a “market perform” rating in a report on Thursday, November 5th. TD Cowen upped their price objective on shares of Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Freedom Broker cut shares of Amgen from a “buy” rating to a “hold” rating and increased their price objective for the stock from $450.00 to $470.00 in a research report on Friday, November 6th. Finally, Weiss Ratings upgraded shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $422.76.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.